Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2013

01-06-2013 | Original Article

Lactulose Mediates Suppression of Dextran Sodium Sulfate-Induced Colon Inflammation by Increasing Hydrogen Production

Authors: Xiao Chen, Xiao Zhai, Jiazi Shi, Wen Wu Liu, Hengyi Tao, Xuejun Sun, Zhimin Kang

Published in: Digestive Diseases and Sciences | Issue 6/2013

Login to get access

Abstract

Background

Molecular hydrogen (H2) is a potent antioxidant and able to protect organs from oxidative stress injuries. Orally administered lactulose, a potent H2 inducer, is digested by colon microflora and significantly increases H2 production, indicating its potential anti-inflammatory action.

Objective

To evaluate the anti-inflammatory effects of lactulose on dextran sodium sulfate (DSS)-induced colitis in mice.

Methods

Mice were randomly assigned into seven groups, receiving regular distilled water, H2-rich saline (peritoneal injection), DSS, oral lactulose (0.1, 0.15, 0.2 ml/10 g, respectively), and lactulose (0.2 ml/10 g) + oral antibiotics. The mouse model of human ulcerative colitis was established by supplying mice with water containing DSS. The H2 breath test was used to determine the exhaled H2 concentration. Body weight, colitis score, colon length, pathological features and tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), maleic dialdehyde (MDA) and marrow peroxidase (MPO) levels in colon lesions were evaluated.

Results

After 7 days, DSS-induced loss of body weight, increase of colitis score, shortening of colon length, pathological changes and elevated levels of TNF-α, IL-1β, MDA, and MPO in colon lesions, were significantly suppressed by oral lactulose administration and intraperitoneally injected H2-rich saline. Ingestion of antibiotics significantly compromised the anti-inflammatory effects of lactulose. The H2 breath test showed that lactulose administration significantly induced hydrogen production and that antibiotics administration could inhibit H2 production.

Conclusion

Lactulose can prevent the development of DSS-induced colitis and alleviate oxidative stress in the colon, as measured by MDA and MPO, probably by increasing endogenous H2 production.
Literature
1.
go back to reference Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33:6S–15S.PubMedCrossRef Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33:6S–15S.PubMedCrossRef
2.
go back to reference Suematsu M, Suzuki M, Kitahora T, et al. Increased respiratory burst of leukocytes in inflammatory bowel diseases—the analysis of free radical generation by using chemiluminescence probe. J Clin Lab Immunol. 1987;24:125–128.PubMed Suematsu M, Suzuki M, Kitahora T, et al. Increased respiratory burst of leukocytes in inflammatory bowel diseases—the analysis of free radical generation by using chemiluminescence probe. J Clin Lab Immunol. 1987;24:125–128.PubMed
3.
go back to reference Karp SM, Koch TR. Oxidative stress and antioxidants in inflammatory bowel disease. Dis Mon. 2006;52:199–207.PubMedCrossRef Karp SM, Koch TR. Oxidative stress and antioxidants in inflammatory bowel disease. Dis Mon. 2006;52:199–207.PubMedCrossRef
4.
go back to reference Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut. 1990;31:786–790.PubMedCrossRef Keshavarzian A, Morgan G, Sedghi S, Gordon JH, Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut. 1990;31:786–790.PubMedCrossRef
5.
go back to reference Neilly PJ, Gardiner KR, Rowlands BJ. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut. 1996;38:475.PubMedCrossRef Neilly PJ, Gardiner KR, Rowlands BJ. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut. 1996;38:475.PubMedCrossRef
6.
go back to reference Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med. 1995;19:911–918.PubMedCrossRef Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Radic Biol Med. 1995;19:911–918.PubMedCrossRef
7.
go back to reference Oz HS, Chen TS, McClain CJ, de Villiers WJ. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem. 2005;16:297–304.PubMedCrossRef Oz HS, Chen TS, McClain CJ, de Villiers WJ. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem. 2005;16:297–304.PubMedCrossRef
8.
go back to reference Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13:688–694.PubMedCrossRef Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007;13:688–694.PubMedCrossRef
9.
go back to reference Huang CS, Kawamura T, Toyoda Y, Nakao A. Recent advances in hydrogen research as a therapeutic medical gas. Free Radic Res. 2010;44:971–982.PubMedCrossRef Huang CS, Kawamura T, Toyoda Y, Nakao A. Recent advances in hydrogen research as a therapeutic medical gas. Free Radic Res. 2010;44:971–982.PubMedCrossRef
10.
go back to reference Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (dss) is characterized by th1 and th2 cytokines. Clin Exp Immunol. 1998;114:385–391.PubMedCrossRef Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (dss) is characterized by th1 and th2 cytokines. Clin Exp Immunol. 1998;114:385–391.PubMedCrossRef
11.
go back to reference Kajiya M, Silva MJ, Sato K, Ouhara K, Kawai T. Hydrogen mediates suppression of colon inflammation induced by dextran sodium sulfate. Biochem Biophys Res Commun. 2009;386:11–15.PubMedCrossRef Kajiya M, Silva MJ, Sato K, Ouhara K, Kawai T. Hydrogen mediates suppression of colon inflammation induced by dextran sodium sulfate. Biochem Biophys Res Commun. 2009;386:11–15.PubMedCrossRef
12.
go back to reference Florent C, Flourie B, Leblond A, Rautureau M, Bernier JJ, Rambaud JC. Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study). J Clin Invest. 1985;75:608–613.PubMedCrossRef Florent C, Flourie B, Leblond A, Rautureau M, Bernier JJ, Rambaud JC. Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study). J Clin Invest. 1985;75:608–613.PubMedCrossRef
13.
go back to reference Kim YJ, Kim EH, Hahm KB. Oxidative stress in inflammation-based gastrointestinal tract diseases: challenges and opportunities. J Gastroenterol Hepatol. 2012;27:1004–1010.PubMedCrossRef Kim YJ, Kim EH, Hahm KB. Oxidative stress in inflammation-based gastrointestinal tract diseases: challenges and opportunities. J Gastroenterol Hepatol. 2012;27:1004–1010.PubMedCrossRef
14.
15.
go back to reference Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.PubMedCrossRef Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.PubMedCrossRef
16.
go back to reference Damiani CR, Benetton CA, Stoffel C, et al. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol. 2007;22:1846–1851.PubMedCrossRef Damiani CR, Benetton CA, Stoffel C, et al. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol. 2007;22:1846–1851.PubMedCrossRef
17.
go back to reference Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis. 2003;24:353–362.PubMedCrossRef Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis. 2003;24:353–362.PubMedCrossRef
18.
go back to reference Hayashida K, Sano M, Ohsawa I, et al. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia–reperfusion injury. Biochem Biophys Res Commun. 2008;373:30–35.PubMedCrossRef Hayashida K, Sano M, Ohsawa I, et al. Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia–reperfusion injury. Biochem Biophys Res Commun. 2008;373:30–35.PubMedCrossRef
19.
go back to reference Fukuda K, Asoh S, Ishikawa M, Yamamoto Y, Ohsawa I, Ohta S. Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. Biochem Biophys Res Commun. 2007;361:670–674.PubMedCrossRef Fukuda K, Asoh S, Ishikawa M, Yamamoto Y, Ohsawa I, Ohta S. Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. Biochem Biophys Res Commun. 2007;361:670–674.PubMedCrossRef
20.
go back to reference Buchholz BM, Kaczorowski DJ, Sugimoto R, et al. Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. Am J Transplant. 2008;8:2015–2024.PubMedCrossRef Buchholz BM, Kaczorowski DJ, Sugimoto R, et al. Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. Am J Transplant. 2008;8:2015–2024.PubMedCrossRef
21.
go back to reference Gharib B, Hanna S, Abdallahi OM, Lepidi H, Gardette B, De Reggi M. Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. C R Acad Sci III. 2001;324:719–724.PubMedCrossRef Gharib B, Hanna S, Abdallahi OM, Lepidi H, Gardette B, De Reggi M. Anti-inflammatory properties of molecular hydrogen: investigation on parasite-induced liver inflammation. C R Acad Sci III. 2001;324:719–724.PubMedCrossRef
22.
go back to reference Chen H, Sun YP, Li Y, et al. Hydrogen-rich saline ameliorates the severity of l-arginine-induced acute pancreatitis in rats. Biochem Biophys Res Commun. 2010;393:308–313.PubMedCrossRef Chen H, Sun YP, Li Y, et al. Hydrogen-rich saline ameliorates the severity of l-arginine-induced acute pancreatitis in rats. Biochem Biophys Res Commun. 2010;393:308–313.PubMedCrossRef
24.
go back to reference Voskuijl W, de Lorijn F, Verwijs W, et al. Peg 3350 (transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut. 2004;53:1590–1594.PubMedCrossRef Voskuijl W, de Lorijn F, Verwijs W, et al. Peg 3350 (transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut. 2004;53:1590–1594.PubMedCrossRef
25.
go back to reference Chen X, Zuo Q, Hai Y, Sun XJ. Lactulose: an indirect antioxidant ameliorating inflammatory bowel disease by increasing hydrogen production. Med Hypotheses. 2011;76:325–327.PubMedCrossRef Chen X, Zuo Q, Hai Y, Sun XJ. Lactulose: an indirect antioxidant ameliorating inflammatory bowel disease by increasing hydrogen production. Med Hypotheses. 2011;76:325–327.PubMedCrossRef
26.
go back to reference Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol. 1979;14:333–336.PubMedCrossRef Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol. 1979;14:333–336.PubMedCrossRef
27.
go back to reference Sen S, Dear KL, King TS, Elia M, Hunter JO. Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14:753–756.PubMedCrossRef Sen S, Dear KL, King TS, Elia M, Hunter JO. Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2002;14:753–756.PubMedCrossRef
28.
go back to reference Hentschel U, Dobrindt U, Steinert M. Commensal bacteria make a difference. Trends Microbiol. 2003;11:148–150.PubMedCrossRef Hentschel U, Dobrindt U, Steinert M. Commensal bacteria make a difference. Trends Microbiol. 2003;11:148–150.PubMedCrossRef
29.
go back to reference Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115–1118.PubMedCrossRef Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115–1118.PubMedCrossRef
30.
go back to reference Panesar PS, Kumari S. Lactulose: production, purification and potential applications. Biotechnol Adv. 2011;29:940–948.PubMedCrossRef Panesar PS, Kumari S. Lactulose: production, purification and potential applications. Biotechnol Adv. 2011;29:940–948.PubMedCrossRef
31.
go back to reference Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis. 2009;15:454–462.PubMedCrossRef Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis. 2009;15:454–462.PubMedCrossRef
32.
go back to reference Kajiya M, Sato K, Silva MJ, et al. Hydrogen from intestinal bacteria is protective for concanavalin a-induced hepatitis. Biochem Biophys Res Commun. 2009;386:316–321.PubMedCrossRef Kajiya M, Sato K, Silva MJ, et al. Hydrogen from intestinal bacteria is protective for concanavalin a-induced hepatitis. Biochem Biophys Res Commun. 2009;386:316–321.PubMedCrossRef
33.
go back to reference Huchzermeyer H, Schumann C. Lactulose—a multifaceted substance. Z Gastroenterol. 1997;35:945–955.PubMed Huchzermeyer H, Schumann C. Lactulose—a multifaceted substance. Z Gastroenterol. 1997;35:945–955.PubMed
34.
go back to reference Hoffmann K, Mossell DAA, Korus W, van de Kamer JH. Investigations on the mode of action of lactulose in the human intestine. Klin Wochenschr. 1964;42:126–130.PubMedCrossRef Hoffmann K, Mossell DAA, Korus W, van de Kamer JH. Investigations on the mode of action of lactulose in the human intestine. Klin Wochenschr. 1964;42:126–130.PubMedCrossRef
35.
go back to reference Schumann C. Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr. 2002;41:I17–I25.PubMedCrossRef Schumann C. Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr. 2002;41:I17–I25.PubMedCrossRef
36.
go back to reference Xie K, Yu Y, Zhang Z, et al. Hydrogen gas improves survival rate and organ damage in zymosan-induced generalized inflammation model. Shock. 2010;34:495–501.PubMedCrossRef Xie K, Yu Y, Zhang Z, et al. Hydrogen gas improves survival rate and organ damage in zymosan-induced generalized inflammation model. Shock. 2010;34:495–501.PubMedCrossRef
37.
go back to reference Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. 2010;16:3347–3357.PubMedCrossRef Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: role of inflammation and oxidative stress. World J Gastroenterol. 2010;16:3347–3357.PubMedCrossRef
38.
go back to reference Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2010;51:1062–1069.PubMedCrossRef Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2010;51:1062–1069.PubMedCrossRef
Metadata
Title
Lactulose Mediates Suppression of Dextran Sodium Sulfate-Induced Colon Inflammation by Increasing Hydrogen Production
Authors
Xiao Chen
Xiao Zhai
Jiazi Shi
Wen Wu Liu
Hengyi Tao
Xuejun Sun
Zhimin Kang
Publication date
01-06-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2563-7

Other articles of this Issue 6/2013

Digestive Diseases and Sciences 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine